- Home
- CORT vs LEGN Comparison
CORT vs LEGN Comparison
Compare CORT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- LEGN
- Stock Information
- Founded
- CORT 1998
- LEGN 2014
- Country
- CORT United States
- LEGN United States
- Employees
- CORT N/A
- LEGN N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- CORT Health Care
- LEGN Health Care
- Exchange
- CORT Nasdaq
- LEGN Nasdaq
- Market Cap
- CORT 7.6B
- LEGN 6.7B
- IPO Year
- CORT N/A
- LEGN 2020
- Fundamental
- Price
- CORT $72.87
- LEGN $33.11
- Analyst Decision
- CORT Strong Buy
- LEGN Strong Buy
- Analyst Count
- CORT 4
- LEGN 12
- Target Price
- CORT $139.00
- LEGN $73.36
- AVG Volume (30 Days)
- CORT 658.4K
- LEGN 1.1M
- Earning Date
- CORT 10-29-2025
- LEGN 11-11-2025
- Dividend Yield
- CORT N/A
- LEGN N/A
- EPS Growth
- CORT N/A
- LEGN N/A
- EPS
- CORT 1.11
- LEGN N/A
- Revenue
- CORT $716,080,000.00
- LEGN $796,838,000.00
- Revenue This Year
- CORT $30.62
- LEGN $70.75
- Revenue Next Year
- CORT $37.68
- LEGN $52.47
- P/E Ratio
- CORT $65.38
- LEGN N/A
- Revenue Growth
- CORT 25.71
- LEGN 74.75
- 52 Week Low
- CORT $35.45
- LEGN $27.34
- 52 Week High
- CORT $117.33
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- CORT 56.90
- LEGN 36.16
- Support Level
- CORT $67.32
- LEGN $33.20
- Resistance Level
- CORT $72.52
- LEGN $34.71
- Average True Range (ATR)
- CORT 2.19
- LEGN 1.22
- MACD
- CORT 0.36
- LEGN -0.09
- Stochastic Oscillator
- CORT 74.30
- LEGN 10.96
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.